// App-Quantinova.ai

345 : Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study

Researchers

Presenter

  • Jason Gotlib

Principal Investigators

  • Deepti H. Radia

  • Tracy I. George

  • William A Robinson

  • Albert T. Quiery

  • Mark W. Drummond

  • Prithviraj Bose

  • Elizabeth O. Hexner

  • Elliott F. Winton

  • Hans-Peter Horny

  • Meera Tugnait

  • Oleg Schmidt-Kittler

  • Erica K. Evans

  • Hui-Min Lin

  • Brenton G. Mar

  • Michael W. Deininger

  • Daniel J. DeAngelo

Medical Centers

  • Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • ARUP Laboratories, University of Utah, Salt Lake City, UT

  • U C Denver, Aurora, CO

  • University of Michigan, Ann Arbor, MI

  • Beaston Inst for Cancer Center, Glasgow, United Kingdom

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Cell Therapy and Transplantation, University of Pennsylvania, Philadelphia

  • Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA

  • Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany

  • Blueprint Medicines Corporation, Cambridge, MA

  • Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

Locations

  • United States

  • United Kingdom

  • Germany

Companies

  • Blueprint Medicines

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Mastocytosis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved